CI vs. LLY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CI and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CI | LLY |
|---|---|---|
| Company Name | The Cigna Group | Eli Lilly and Company |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Pharmaceuticals |
| Market Capitalization | 72.67 billion USD | 916.61 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 31, 1982 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CI and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CI | LLY |
|---|---|---|
| 5-Day Price Return | 4.45% | 6.07% |
| 13-Week Price Return | -9.16% | 46.21% |
| 26-Week Price Return | -10.68% | 37.43% |
| 52-Week Price Return | -18.79% | 26.30% |
| Month-to-Date Return | 10.33% | 18.82% |
| Year-to-Date Return | -2.35% | 32.81% |
| 10-Day Avg. Volume | 3.12M | 5.24M |
| 3-Month Avg. Volume | 1.91M | 4.43M |
| 3-Month Volatility | 44.35% | 32.04% |
| Beta | 0.25 | 0.32 |
Profitability
Return on Equity (TTM)
CI
15.06%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
CI’s Return on Equity of 15.06% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
LLY
102.26%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
LLY’s Return on Equity of 102.26% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
CI
2.29%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
CI’s Net Profit Margin of 2.29% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
LLY
30.99%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 30.99% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
CI
3.45%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
CI’s Operating Profit Margin of 3.45% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
LLY
38.84%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
An Operating Profit Margin of 38.84% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | CI | LLY |
|---|---|---|
| Return on Equity (TTM) | 15.06% | 102.26% |
| Return on Assets (TTM) | 3.99% | 19.18% |
| Net Profit Margin (TTM) | 2.29% | 30.99% |
| Operating Profit Margin (TTM) | 3.45% | 38.84% |
| Gross Profit Margin (TTM) | 9.55% | 83.03% |
Financial Strength
Current Ratio (MRQ)
CI
0.83
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
CI’s Current Ratio of 0.83 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
LLY
1.55
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
LLY’s Current Ratio of 1.55 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CI
0.81
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
CI’s Debt-to-Equity Ratio of 0.81 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
LLY
1.79
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.79. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
CI
2.32
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
CI’s Interest Coverage Ratio of 2.32 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | CI | LLY |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 1.55 |
| Quick Ratio (MRQ) | 0.73 | 0.74 |
| Debt-to-Equity Ratio (MRQ) | 0.81 | 1.79 |
| Interest Coverage Ratio (TTM) | 2.32 | 20.36 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CI
2.22%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Yield of 2.22% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
LLY
0.54%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
LLY’s Dividend Yield of 0.54% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
CI
26.01%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
CI’s Dividend Payout Ratio of 26.01% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
LLY
28.28%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 28.28% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | CI | LLY |
|---|---|---|
| Dividend Yield (TTM) | 2.22% | 0.54% |
| Dividend Payout Ratio (TTM) | 26.01% | 28.28% |
Valuation
Price-to-Earnings Ratio (TTM)
CI
11.72
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
In the lower quartile for the Health Care Providers & Services industry, CI’s P/E Ratio of 11.72 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
LLY
52.64
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
A P/E Ratio of 52.64 places LLY in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
CI
0.27
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, CI’s P/S Ratio of 0.27 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
LLY
16.31
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
With a P/S Ratio of 16.31, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
CI
1.84
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
CI’s P/B Ratio of 1.84 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
LLY
30.35
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
At 30.35, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | CI | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 11.72 | 52.64 |
| Price-to-Sales Ratio (TTM) | 0.27 | 16.31 |
| Price-to-Book Ratio (MRQ) | 1.84 | 30.35 |
| Price-to-Free Cash Flow Ratio (TTM) | 7.50 | 120.60 |